A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

Clinical trial NCT07633756 · RECRUITING

Trial details

NCT number: NCT07633756
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Phase 1b Open Label REC-617 RB1-Negative Leiomyosarcoma

Start date: 2026-10-19
Primary completion: 2029-12-26
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.